Access to Market Share and Survey Data for Food Supply Monitoring and Surveillance of the U.S. Market

The U.S. Food and Drug Administration, through its Office of Acquisitions and Grants Services in Rockville, Maryland, is procuring exclusive access to national retail market share and survey data to support food supply monitoring and post-market surveillance under solicitation FDASS134285. The acquisition is conducted as a sole source firm-fixed-price purchase order under FAR Part 13 and FAR 6.302-1, justified by Circana, Inc.’s unique and non-replaceable possession of proprietary retail scanner data covering the past five rolling years of the U.S. market. This data is critical for FDA’s public health research, predictive surveillance, and policy development related to FDA-regulated consumer goods, with no competitive solicitation taking place due to the absence of alternative sources capable of delivering the required dataset. The contract requires continuous electronic access to comprehensive consumer purchase and market share information, with no physical deliveries, packaging, or shipping terms applicable, and performance is deemed to occur at the FDA’s headquarters in Rockville, MD, even though the data provider is based in Chicago, Illinois. The solicitation was posted on June 29, 2026, with responses due by July 6, 2026, and all submissions must be sent via email to Telisha Wilson, the designated point of contact. No formal evaluation factors, weights, or technical scoring criteria apply due to the sole source nature of the award, and no competitive pricing analysis is conducted. No specific contract clauses, representations, certifications, or statements from the offeror are provided in the documentation, nor are there details on payment offices, accounting codes, invoicing systems, or contractual roles such as COR or PCO. The acquisition falls under NAICS code 541990 and does not utilize any set-aside provisions, with no socioeconomic, small business, or other affirmative classification requirements cited. Data accuracy, timeliness, and completeness are implied as performance standards, though no formal inspection criteria or quality standards are explicitly outlined. The contract term is not explicitly stated, but the requirement for five years of rolling data suggests an ongoing service period aligned with FDA’s long-term surveillance needs, with no options, special personnel requirements, or security clearances identified.